The BLRX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the BLRX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The BLRX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
|View BLRX Detailed Price Forecast - CNN Money||View BLRX Detailed Summary - Google Finance|
|View BLRX Detailed Summary - Yahoo! Finance||View BLRX Stock Research & Analysis - Zacks.com|
|View BLRX Trends & Analysis - Trade-Ideas||View BLRX Major Holders - Barrons|
|View BLRX Call Transcripts - NASDAQ||View BLRX Breaking News & Analysis - Seeking Alpha|
|View BLRX Annual Report - CompanySpotlight.com||View BLRX OTC Short Report - OTCShortReport.com|
|View BLRX Fundamentals - TradeKing||View BLRX SEC Filings - Bar Chart|
|View Historical Prices for BLRX - The WSJ||View Performance/Total Return for BLRX - Morningstar|
|View the Analyst Estimates for BLRX - MarketWatch||View the Earnings History for BLRX - CNBC|
|View the BLRX Earnings - StockMarketWatch||View BLRX Buy or Sell Recommendations - MacroAxis|
|View the BLRX Bullish Patterns - American Bulls||View BLRX Short Pain Metrics - ShortPainBot.com|
|View BLRX Stock Mentions - StockTwits||View BLRX Stock Mentions - PennyStockTweets|
|View BLRX Stock Mentions - Twitter||View BLRX Investment Forum News - Investor Hub|
|View BLRX Stock Mentions - Yahoo! Message Board||View BLRX Stock Mentions - Seeking Alpha|
|View Insider Transactions for BLRX - SECform4.com||View Insider Transactions for BLRX - Insider Cow|
|View BLRX Major Holdings Summary - CNBC||View Insider Disclosure for BLRX - OTC Markets|
|View Insider Transactions for BLRX - Yahoo! Finance||View Institutional Holdings for BLRX - NASDAQ|
|View BLRX Stock Insight & Charts - FinViz.com||View BLRX Investment Charts - StockCharts.com|
|View BLRX Stock Overview & Charts - BarChart||View BLRX User Generated Charts - Trading View|
BioLineRx to Present at 2018 BIO CEO & Investor Conference in New York on February 13
Posted on Tuesday February 06, 2018
TEL AVIV, Israel , Feb. 6, 2018 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that its Chief ...
BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA) a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today the publication of data showing that BL-8040, its lead oncology platform, augments the ability of the immune system to fight cancer by increasing the infiltration of anti-tumor-specific T-cells into the tumor microenvironment (TME), resulting in decreased tumor growth and prolonged survival in a murine model of cancer. Results of the study will be presented as a poster titled "CXCR4 Antagonist (BL-8040) Enhances Antitumor Effects by Increasing Tumor Infiltration of Antigen-specific Effector T-cells" (Abstract 73) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. In the preclinical study, a murine model of cancer was used to assess the effects of BL-8040 in combination with a cancer vaccine that primes the immune system against the tumor.
BioLineRx Reports Data at ASCO-SITC Conference Showing Complete Tumor Regression by AGI-134 in Pre-Clinical Studies
Posted on Tuesday January 23, 2018
BioLineRx Ltd. (BLRX) (BLRX) (BLRX.TA), a clinical-stage biopharmaceutical company focused on oncology and immunology, announced today that AGI-134, an immunotherapy compound in development for the treatment of multiple solid tumors, demonstrated successful results in two pre-clinical melanoma studies. Results of these studies will be presented as a poster titled "Intratumoral Administration of the Alpha-Gal Glycolipid AGI-134 to Induce Tumor Regression in a Mouse Model of Melanoma" (Abstract 68) on January 25, 2018 at the ASCO-SITC Clinical Immuno-Oncology Symposium, being held January 25-27, 2018, in San Francisco, CA. The ability of intratumorally injected AGI-134 to induce regression of established primary tumors was assessed in two murine melanoma models.
BioLineRx Cancer Drug Positive as Monotherapy in Phase IIa
Posted on Thursday January 18, 2018
BioLineRx (BLRX) posts encouraging partial results from the monotherapy portion of a phase IIa COMBAT study, assessing its lead pipeline candidate, BL-8040, for pancreatic cancer patients.